SeaStar Medical’s Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiative (ADQI) Meeting
07 nov. 2022 12h30 HE
|
SeaStar Medical Holding Corporation
– The SCD is currently being evaluated by the FDA for a Humanitarian Device Exemption (HDE) marketing approval for use in children (> 20 kgs) with AKI – The Company expects the FDA to complete...
LMF Acquisition Opportunities and SeaStar Medical Announce Effectiveness of Registration Statement and Special Meeting of Stockholders to be Held October 18, 2022 to Approve Business Combination
28 sept. 2022 17h00 HE
|
LMF Acquisition Opportunities Inc.
All stockholders of LMF Acquisition Opportunities as of September 23, 2022 are encouraged to vote their shares as soon as possible before the special meeting Stockholders who need assistance voting...
SeaStar Medical Appoints Dr. Sai Prasad Iyer, Ph.D as VP, Medical Affairs and Clinical Development
19 sept. 2022 08h30 HE
|
LMF Acquisition Opportunities Inc.
Denver, Colo. and Tampa, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on...
SeaStar Medical Reports First Successful Treatment of Pediatric Patient with Hemophagocytic Lymphohistiocytosis (HLH) and Multi-Organ Failure with its SCD
01 août 2022 08h00 HE
|
LMF Acquisition Opportunities Inc.
DENVER, CO and TAMPA, FL, Aug. 01, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...
SeaStar Medical Submits Humanitarian Device Exemption Application to FDA for Use of Selective Cytopheretic Device in Children with Acute Kidney Injury
20 juil. 2022 08h00 HE
|
LMF Acquisition Opportunities Inc.
DENVER, CO and TAMPA, FL, July 20, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...
SeaStar Medical Announces Publication of Clinical Trial Results Demonstrating its SCD Significantly Lowered Mortality Rates among Critically Ill ICU COVID-19 Patients by Safely and Effectively Stopping Inflammation Causing Cytokine Storms
07 juin 2022 08h30 HE
|
LMF Acquisition Opportunities Inc.
DENVER, CO and TAMPA, FL, June 07, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital...
SeaStar Medical Appoints Kevin Chung, MD as Chief Medical Officer
24 mai 2022 08h00 HE
|
LMF Acquisition Opportunities Inc.
DENVER, CO and TAMPA, FL, May 24, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Inc., a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital...
SeaStar Medical Granted FDA Breakthrough Device Designation for a Novel Immunomodulatory Therapy for Acute Kidney Injury Patients
03 mai 2022 08h00 HE
|
LMF Acquisition Opportunities Inc.
DENVER, CO and TAMPA, FL, May 03, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...